Results 221 to 230 of about 9,980,709 (276)

Mapping the Radiopharmaceutical Therapy Landscape for Prostate Cancer: Insights Into Global Clinical Trial Trends and Future Directions

Med Research, EarlyView.
Zhiwu Dong, Sixiang Yan, Xiaodong Liu, Peng Gu   +3 more
wiley   +1 more source

Electrocatalytically Amplified Immunosensing Enabled by Titanium Oxynitride‐Supported Ru Nanodots on Graphene Oxide Hybrid Architecture

Small, EarlyView.
A synergistic effect among the electrocatalytic Ru/TiON‐GO nanocomposite, biorecognition elements, and the [Fe(CN)6]3−/4− redox probe for highly sensitive and selective impedimetric detection of PSA protein in human serum was demonstrated. The immunosensor exhibited a limit of detection of only 0.06 ng mL−1 PSA protein, underscoring the importance and ...
Mitja Koderman, Milutin Smiljanić, Filip Cernatič, Marjan Bele, Francisco Ruiz‐Zepeda, Nejc Hodnik, Mitja Kolar, Samo B. Hočevar, Nikola Tasić   +8 more
wiley   +1 more source

Identification and Discrimination of Sulfated and Unsulfated Gut‐Hormone Biomarkers in Human Serum by Nanopore

Small, EarlyView.
This study discriminates between sulfated and unsulfated cholecystokinin‐8 gut‐hormone forms at single‐molecule‐level resolution. Using an aerolysin nanopore embedded in a hybrid lipid‐polymer membrane, the system produces distinct electrical signatures enabling highly sensitive detection, even in 20% human serum.
Luca Iesu, Laurent Bacri, Juan Pelta, Benjamin Cressiot   +3 more
wiley   +1 more source

Delafloxacin suppresses DEPDC1 expression and induces G2/M arrest in non‐small cell lung cancer cells: A drug repurposing study

Smart Molecules, EarlyView.
This study presents Delafloxacin repurposed as a DEPDC1‐targeting therapeutic aiming to suppress lung cancer progression. It highlights a novel strategy for lung cancer treatment with potential clinical applications. Abstract Emerging evidence highlights the oncogenic role of the Dishevelled, Egl‐10, and Pleckstrin domains containing 1 (DEPDC1) gene in
Noman Ali, Farishta Shafiq, Mishal Iftikhar, Muhammad Shahzad Zafar, Muhammad Shoaib   +4 more
wiley   +1 more source

Targeting the CD47–SIRPα phagocytic checkpoint in cancer: Biology, translational opportunities, and next‐generation therapeutic strategies

Smart Molecules, EarlyView.
The CD47–SIRPα axis has emerged as a critical innate immune checkpoint that suppresses macrophage‐mediated phagocytosis through a canonical “don't eat me” signal and enables tumor immune evasion. We comprehensively summarize the structural and biological features of CD47 and the molecular mechanisms underlying CD47‐mediated regulation of phagocytosis ...
Ruimei Zhou, Lingjie Jing, Jianping Zhang, Cheng Guo, Quanjun Yang   +4 more
wiley   +1 more source

Diagnostic Performance of Prostate-specific Antigen Density for Detecting Clinically Significant Prostate Cancer in the Era of Magnetic Resonance Imaging: A Systematic Review and Meta-analysis. [PDF]

Eur Urol Oncol
Wang S, Kozarek J, Russell R, Drescher M, Khan A, Kundra V, Barry KH, Naslund M, Siddiqui MM.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

The Performance of Prostate Specific Antigen, Prostate Specific Antigen Density and Transition Zone Density in the Era of Extended Biopsy Schemes

Journal of Urology, 2008
Prostate specific antigen, prostate specific antigen density and transition zone density have been previously identified as prostate cancer detection tools. Recent studies suggest that prostate specific antigen may be increasingly accurate for detecting clinically significant high grade prostate cancer (Gleason grade 7 or greater).
Christopher Elliott, Rajesh Shinghal
exaly   +3 more sources

Prostate specific antigen and prostate specific antigen density. Roles in patient evaluation and management

Cancer, 1994
Prostate specific antigen (PSA) is the most accurate serum marker for prostate cancer. However, sensitivity and specificity are suboptimal, especially at the intermediate levels between 4.1 and 10.0 ng/ml (monoclonal). For intermediate PSA levels, PSA density (PSAD) provides unique information regarding the need for biopsy and the likelihood of ...
Mitchell C Benson, Carl A Olsson
exaly   +3 more sources

The use of prostate specific antigen density to improve the sensitivity of prostate specific antigen in detecting prostate carcinoma

Cancer, 1994
Prostate specific antigen (PSA) is useful as a tumor marker for monitoring patients with prostate cancer after definitive therapy. Limitations have been noted when PSA was used for the early detection of prostate cancer. The use of prostate specific antigen density [PSAD = PSA (ng/ml)/prostate volume (cc)] has been suggested to differentiate benign ...
W P Evans
exaly   +3 more sources